

Allergy Therapeutics

Biomarker data confirm VLP Peanut hypoallergenicity

3 August 2021

- The VLP-Peanut 001 *ex vivo* biomarker study carried out in conjunction with Imperial College London has reported positive results. This study, focused on evaluating safety, confirmed both the hypoallergenicity of this first VLP (virus-like particle) based peanut allergy vaccine candidate and the proposed design of the Phase I PROTECT first-in-human trial (outlined in our [July 2021 Update](#)), on track to initiate in Q122.
- Human blood samples from peanut allergic individuals were used to evaluate an extensive range of functional and molecular biomarkers and assess the potential for an allergic reaction following dosing with VLP Peanut. The study achieved its primary outcome, confirming VLP Peanut was hypoallergenic: basophil activation and histamine release post challenge was 24-fold lower vs with recombinant peanut extract. Analysis of secondary endpoints is yet to be completed.
- This new data will be included in the VLP Peanut IND application, which will be submitted to the FDA in late-2021, supplement the existing preclinical research package that demonstrated sustained immunological protection following peanut exposure after one single vaccination. An extensive multiple dose toxicology study with the VLP Peanut vaccine candidate has also completed, using the maximum subcutaneous doses expected to be administered in the PROTECT Phase I trial.
- The VLP Peanut vaccine candidate is a novel immunogenic, protective, and non-reactogenic short-course subcutaneous vaccine based on immunologically optimized Cucumber Mosaic Virus-derived VLPs (CuMVT) that display the major peanut allergen (Ara h 2) on its surface. Further information will be presented by Allergy Therapeutics on its VLP Peanut vaccine candidate and VLP technology at a key opinion leader event and investor day in September 2021.

Price	26.85p
Market Cap	£172.3m
Primary exchange	AIM
Sector	Healthcare
Company Code	AGY
Corporate client	Yes

Company description:

Allergy Therapeutics specialises in the diagnosis and treatment of allergy. The existing European business generates c £80m annual sales. Near-term R&D efforts are focussed on the Pollinex Quattro platform, whilst in the medium-term the VLP platform is highly promising.

Trinity Delta view: The positive biomarker study results pave the way for an IND submission in late-2021 and Phase I trial start in Q122. As peanut allergy is one of the most common food allergies, and a leading cause of severe and fatal food-induced anaphylactic reactions, it was imperative to establish that the VLP Peanut vaccine candidate is hypoallergenic. The data also increase confidence in the clinical relevance of the encouraging preclinical data, although it will be the results of the PROTECT trial that confirm this. With US patents granted, and applications in the national phase in other regions, Allergy Therapeutics is now able to make further VLP-related disclosures at its KOL event. Ahead of this, and top-line results of the Grass MATA MPL G309 exploratory field study anticipated in calendar H221, we continue to value Allergy Therapeutics at £344.5m (53.8p/share). Our SOTP includes a DCF of the commercial operations (£89.7m or 14.0p/share), an rNPV of the R&D pipeline (£210.3m, or 32.8p/share), and net cash (6.9p/share). Positive clinical data from the VLP Peanut and Grass MATA MPL programmes has the potential to unlock further upside.

Analysts

Lala Gregorek

lgregorek@trinitydelta.org

+44 (0) 20 3637 5043

Franco Gregori

fgregori@trinitydelta.org

+44 (0) 20 3637 5041

Lala Gregorek

lgregorek@trinitydelta.org
+44 (0) 20 3637 5043

Franco Gregori

fgregori@trinitydelta.org
+44 (0) 20 3637 5041

Disclaimer

Trinity Delta Research Limited ("TDRL"; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited ("ED"). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publicly available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves ('issuer financed research') and as such is not deemed to be independent, as defined by the FCA, but is 'objective' in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at www.fisma.org. TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2021 Trinity Delta Research Limited. All rights reserved.

More information is available on our website: www.trinitydelta.org